Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. The results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining venetoclax with melphalan or carfilzomib produced additive or better cell death in four of the five cell lines tested. The most striking results were seen with dexamethasone (Dex). Co-treatment of human myeloma cell lines and primary patient samples, with Dex and venetoclax, significantly increased cell death over venetoclax alone in four of the five cell lines, and in all patient samples tested. The mechanism by which this occurs is an increase in the expression of both Bcl-2 and Bim upon addition of Dex. This results in alterations in Bim binding to anti-apoptotic proteins. Dex shifts Bim binding towards Bcl-2 resulting in increased sensitivity to venetoclax. These data suggest that knowledge of drug-induced alterations of Bim-binding patterns may help inform better combination drug regimens. Furthermore, the data indicate combining this novel therapeutic with Dex could be an effective therapy for a broader range of patients than would be predicted by single-agent activity.
INTRODUCTION
Enormous advances in available therapeutics for the treatment of multiple myeloma have been made within the past 15 years. With Food and Drug Administration approval of immunomodulatory drugs, proteasome inhibitors and histone deacetylase inhibitors, 5-year survival rates are now over 47%. 1 However, despite these advances most patients will relapse and develop drug resistant disease. Ultimately, new therapeutic approaches used in combination with the current active agents must be developed.
The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway and represents a novel target. The Bcl-2 family can be divided into four categories: the anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-x L , Bcl-w and Bfl-1), the pro-apoptotic 'sensitizer' BH3-only proteins (Noxa, Bad, Bmf and Bik), the pro-apoptotic 'activator' BH3-only proteins (Bim, Bid and Puma) and the pro-apoptotic effector proteins (Bak and Bax). [2] [3] [4] [5] [6] Activator BH3-only proteins bind to the effector proteins, Bak and Bax, triggering them to oligomerize at the mitochondria and induce mitochondrial outer membrane permeabilization resulting in cytochrome c release and apoptosis. [2] [3] [4] [5] [6] Anti-apoptotic proteins function by sequestering the activator proteins, thereby preventing them from activating the effector proteins. The BH3-only 'sensitizer' proteins are unable to activate Bak and Bax, and function by binding to the anti-apoptotic proteins leading to the release of the activator proteins and thus apoptosis. [2] [3] [4] [5] [6] ABT-737, or the orally bioavailable ABT-263 (navitoclax), are smallmolecule antagonists that mimic the binding of the BH3 domain of Bad to the anti-apoptotic proteins Bcl-2, Bcl-x L and Bcl-w, thereby releasing any bound pro-apoptotic proteins to induce apoptosis. 7, 8 Although initial results from clinical trials in Bcl-2-dependent hematologic malignancies with navitoclax were promising, the efficacy is limited by dose-dependent thrombocytopenia. [9] [10] [11] [12] In an effort to circumvent this adverse effect caused by the inhibition of Bcl-x L , navitoclax has been re-engineered to specifically target Bcl-2.
The new orally bioavailable compound, venetoclax, demonstrated minimal effects on platelets, both in vivo and ex vivo. 13 Pre-clinical studies have demonstrated strong activity in cell lines, patient samples and mouse xenograft models from Bcl-2dependent malignancies such as chronic lymphocytic leukemia and acute myeloid leukemia. 13, 14 In addition, potent cell killing was seen in disease subsets of non-Hodgkin's lymphoma and a subset of multiple myeloma [t (11;14) ]. 13, 15 Given the promising pre-clinical data, it is not surprising that single agent and combination venetoclax clinical trials are now underway for chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma and relapsed refractory multiple myeloma.
We have previously reported on a method of predicting sensitivity of myeloma cell lines and patient samples to the Bcl-2/x L inhibitor ABT-737, based on the binding pattern of pro-apoptotic protein Bim to anti-apoptotic proteins Mcl-1, Bcl-x L and Bcl-2. 16 In Mcl-1-dependent myeloma cells, Bim is primarily associated with Mcl-1, and are insensitive to ABT-737. In contrast, in myeloma cells that are co-dependent on Mcl-1 and Bcl-2/x L for survival, Bim is either predominantly associated with Bcl-2/x L or when it is released from Bcl-2/x L it can not bind to Mcl-1 because of the presence of the Mcl-1 inhibitor Noxa. As the adverse events associated with navitoclax limit its utility in the treatment of multiple myeloma, we sought to investigate the applicability of this method to venetoclax, as well as determine its efficacy in a broad range of cell lines and patient samples alone and in combination with standard myeloma therapies. line was obtained from Dr Steven Rosen (Northwestern University, Chicago, IL, USA), KMS11 and KMS18 cell lines were provided by Dr P Leif Bergsagel (Mayo Clinic, Scottsdale, AZ, USA) and OPM2 by Nizar Bahlis (University of Calgary). Cells were maintained on supplemented RPMI-1640 media, as previously described. 17 Reagents Propidium iodide, melphalan (MEL) and dexamethasone (Dex) were purchased from Sigma-Aldrich (St Louis, MO, USA); Annexin V-fluorescein isothiocyanate was purchased from Biovision (Palo Alto, CA, USA). Carfilzomib was generously provided by Onyx Pharmaceuticals (San Francisco, CA, USA) and venetoclax by AbbVie (Chicago, IL, USA).
Apoptosis assays
Cell death was measured by Annexin V-fluorescein isothiocyanate and propidium iodide staining as previously described. 18 
Antibodies
The following primary antibodies were used for western blot: mouse anti-Noxa mAb (Abcam, Cambridge, MA, USA); rabbit anti-Bim pAb (EMD Millipore, Temecula, CA, USA); rabbit anti-Mcl-1 pAb (Enzo Life Sciences, Farmingdale, NY, USA); rabbit anti-Bcl-x L pAb (Cell Signaling Technology, Danvers, MA, USA); rabbit anti-Bcl-2 pAb (Cell Signaling Technology); and mouse anti-β-actin mAb (Sigma-Aldrich). For co-immunoprecipitation (Co-IP), the following primary antibodies were used: mouse anti-Mcl-1 mAb (BD Biosciences, San Jose, CA, USA); hamster anti-Bcl-2 mAb (BD Biosciences); and mouse anti-Bcl-x L mAb (7B2.5). 19 For western blotting, the following secondary antibodies were used: anti-mouse IgG 1 -HRP conjugate (Santa Cruz Biotechnology, Dallas, TX, USA); ECL rabbit IgG-HRP-linked whole antibody (from donkey; GE Healthcare Life Sciences, Piscataway, NJ, USA). The secondary antibody used for Co-IP was provided in the Exacta-Cruz C Kit (Santa Cruz Biotechnology).
Western blot analysis
Western blotting was performed using standard techniques as previously described. 17 
Co-immunoprecipitation studies
Immunoprecipitation experiments were performed using the Exacta-Cruz C Kit (Santa Cruz Biotechnology) following the manufacturer's instructions as previously described. 17 siRNAs Small interfering RNAs (siRNAs) were purchased from Dharmacon (GE Life Sciences). ON-TARGETplus SMART pool siRNA against Noxa (PMAIP1) and the siCONTROL non-targeting siRNA [si(-)] were used per manufacturer's protocol.
Real-time PCR
Real time was performed as previously described, 17 using Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY, USA) and amplified using the TaqMan Gene Expression Master Mix (Life Technologies) on the 7500 Fast Real-Time PCR System following the manufacturer's protocol (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA).
Patient sample processing
All samples were collecting, following an Emory University Institutional Review Board-approved protocol as previously described. 16 
RESULTS
Venetoclax is ineffective at inducing apoptosis in multiple myeloma cell lines In order to determine the activity of venetoclax in multiple myeloma, we treated five human myeloma cell lines with increasing concentrations of venetoclax and examined the induction of apoptosis after 24 h. Consistent with previous findings, 15 only one cell line tested, RPMI8226 (8226), showed an appreciable dose response, although this line was relatively insensitive, with an IC50 of 2.2 μM (Figure 1a ). The remaining cell lines were resistant to the drug, with IC50s ranging from 6.2 μM for MM.1s to 24.7 μM for KMS11.
Previous work from our lab has demonstrated that the sensitivity of 8226 cells to the Bcl-2/Bcl-x L inhibitor ABT-737 was due to the high expression of Noxa in this cell line. 16 Therefore, we wanted to determine if Noxa had a similar role in the response of 8226 to venetoclax. We transfected 8226 cells with either control or Noxa siRNAs before the treatment with venetoclax. We were able to silence approximately half of the Noxa expression (Supplementary Figure S1 ), and in doing so, protected the cells from venetoclax-induced apoptosis (Figure 1b ).
The insensitivity observed with venetoclax in KMS18 was unexpected, as we have previously published data demonstrating the efficacy of ABT-737 at killing this line, as well as evidence that this sensitivity was due to Bim binding to Bcl-2. 16 To further investigate this lack of response to venetoclax, we performed Co-IP studies on KMS18 cells pre-and post-treatment ( Figure 1c ).
Consistent with our previous results, Bim binding in KMS18 cells is concentrated on Bcl-2 and Mcl-1. Upon treatment with venetoclax, Bim is released from Bcl-2; however, it is redistributed to Mcl-1. Therefore, the released Bim is not available to activate Bak and Bax, and initiate apoptosis.
Venetoclax is active in combination with therapeutic agents commonly used in the treatment of multiple myeloma As treatment of myeloma with a single agent is rare, we wanted to investigate the ability of venetoclax to affect the responses of Figure 2 . Venetoclax is highly active in combination therapy. KMS18, 8226, MM.1s, KMS11 and OPM2 were treated with indicated concentrations of venetoclax alone or in combination with the indicated concentration of (a) carfilzomib or (c) dexamethasone for 24 h. (b) KMS18 was treated with carfilzomib for 24 h and protein lysates subjected to input analysis and co-immunoprecipitation as described in myeloma cell lines to agents commonly used in myeloma treatment, such as MEL, carfilzomib, and Dex. We performed venetoclax dose curves similar to those presented in Figure 1 , in the presence or absence of a single concentration of the additional myeloma drug.
MEL is a DNA alkylating agent used in the treatment of multiple myeloma and other cancers. 20 In all cases, the addition of a single concentration of MEL resulted in a left shift of the response curve (Supplementary Figure S2A ). In 8226, KMS11 and OPM2 cell lines this shift resulted in a parallel response curve, which is indicative of an additive interaction. In contrast, in KMS18 and MM.1s cells, especially at the lower end of the dose curves, the change in the slope of the curve indicates a greater than additive interaction.
Carfilzomib is a highly active second-generation proteasome inhibitor used in the treatment of relapse and refractory myeloma. 21 Combining carfilzomib with venetoclax produced a greater than additive response in only one of the cell lines we tested, KMS18 (Figure 2a and Supplementary Figure S2B ). Proteasome inhibitors are known to induce the Mcl-1 inhibitor Noxa 22 and we have observed this in myeloma cell lines with carfilzomib (manuscript in revision). Induction of Noxa would be expected to result in displacement of Bim from Mcl-1. To test this possibility, we co-immunoprecipitated Mcl-1, Bcl-x L and Bcl-2 using monoclonal antibodies 24 h following treatment with carfilzomib and determined the distribution of Bim. As seen in Figure 2b , nearly half of all the bound Bim is found on Bcl-2. Addition of carfilzomib results in a shift in the distribution of Bim from both Bcl-x L and Mcl-1 to Bcl-2. This should make these cells more Bcl-2 dependent and therefore more sensitive to venetoclax. In order to verify that this mechanism is unique to KMS18, we co-immunoprecipitated Mcl-1, Bcl-x L and Bcl-2 in MM.1s following 24 h carfilzomib treatment and found no change in the Bim-Bcl-2 binding (Supplementary Figure S3 ).
Dex is a glucocorticoid steroid used in combination with multiple therapeutic agents in multiple myeloma. The cotreatment of myeloma cell lines with venetoclax and Dex produced the greatest response among the combinations tested with greater than additive responses seen in four of the five cell lines tested (Figure 2c ), the exception being 8226. The largest increases in response to the combination were seen at the low end of the dose curves, suggesting that Dex is making cells exquisitely Bcl-2 dependent.
Cell death induced by the combination of venetoclax and dexamethasone is mediated by changes in expression of the Bcl-2 family Given the striking apoptotic response generated by the cotreatment of myeloma cells with venetoclax and Dex, we next sought to determine the mechanism. MM.1s and KMS18 cells were treated with two concentrations of venetoclax and a single concentration of Dex alone or in combination for 24 h. For each condition, cells were collected for RNA extraction and subjected to real-time PCR. Changes in the mRNA levels of five members of the Bcl-2 family were examined (Figure 3a and Supplementary Figure S4 ). Common to both cells lines, treatment with Dex, either alone or in combination with venetoclax, increased the mRNA levels of Bim. In addition an increase in Bcl-2 was observed in MM.1s. However, venetoclax alone resulted in minimal changes. In order to determine if these changes in mRNA levels translated into changes in protein expression, western blot analysis was performed. Although the changes seen in protein expression were not to the same magnitude as those seen in mRNA, Bim and Bcl-2 protein levels were increased in response to Dex and Bcl-x L decreased in response to co-treatment ( Figure 3b ). In addition, we noticed increased expression of both Noxa and Mcl-1 in response to venetoclax treatment in KMS18 cells. Together these events suggest that Dex shifts cells to a more Bcl-2-dependent state.
Dexamethasone treatment induces alterations in the binding pattern of Bim to anti-apoptotic proteins resulting in increased Bcl-2 dependence The pattern of Bim binding to anti-apoptotic Bcl-2 proteins is a better predictor of sensitivity than expression levels. 16 Therefore, MM.1s ( Figure 4a ) and KMS18 (Figure 4b ) cell lines were treated with venetoclax and Dex alone or in combination, then lysed and co-immunoprecipitated with antibodies against Mcl-1, Bcl-2 and Bcl-x L . The relative levels of Bim bound to each antiapoptotic under each treatment condition was then determined. Consistent with our previous findings, the control pattern of Bim binding in MM.1s and KMS18 differed; however, alterations in the pattern due to drug treatment were similar. As shown in Figure 1c , treatment with venetoclax alone leads to release of Bim from Bcl-2 and subsequent increased Bim bound to Mcl-1. Interestingly, treatment with Dex in both cell lines resulted in increased binding of Bim to all three anti-apoptotic proteins, but with the most striking increase in Bcl-2 binding. Therefore upon co-treatment, a greater amount of Bim is released from Bcl-2 than in cells treated with venetoclax alone. These findings extend the data from Figure 3 , demonstrating that the Dexinduced increase in Bim expression results in higher levels of apoptotic priming and an increase in the proportion of Bim bound to Bcl-2. In contrast, venetoclax has little effect on the amount of bound Bim, but drastically changes the distribution towards a Mcl-1 dependent phenotype. The combination treatment results in a reduction of the total bound Bim to levels that are similar (MM.1s) or less than (KMS18) control levels due to the release of nearly all the Bcl-2 bound Bim. As the total bound Bim is released, the data suggest it has been released to activate Bax/Bak.
Plasma cells from myeloma patients that are insensitive to venetoclax alone become highly sensitive with the addition of low-dose dexamethasone
In order to determine if the response seen in myeloma cell lines could be reproduced in patient samples, we performed dose curves with venetoclax as a single agent or in combination with Dex on cells isolated from bone marrow aspirates donated by multiple myeloma or plasma cell leukemia patients, with varying genetic backgrounds (Table 1 ). In each sample tested, the addition of Dex to venetoclax treatment decreased the IC50 over venetoclax alone, with fold changes ranging from 1.3 to 25 ( Table 2 ). Figure 5 contains dose curves and Co-IP data from two representative samples, chosen for their similarity to commonly used myeloma cell lines. MM74 had a Bim-binding pattern and dose response very similar to that of the cell line KMS18, whereas MM54-2 is similar to MM.1s.
DISCUSSION
Here we have taken advantage of the role the Bcl-2 family of proteins have in regulating apoptosis, the fact they are commonly overexpressed in hematologic malignancies, and a method we generated to gauge the reliance of myeloma cells on anti- Figure 5 . A synergistic response to the combination of venetoclax and dexamethasone in plasma cells from myeloma patients. Two million total cells from buffy coats were resuspended in medium for culture, whereas the remaining cells were subjected to CD138+ cell isolation. Cells were treated with the indicated concentrations of venetoclax either alone or in combination with 0.5 μM dexamethasone for 24 h. Apoptosis was determined by staining with antibodies against CD38, CD45 and Annexin V-fluorescein isothiocyanate. Lysates were obtained from isolated CD138+ cells and protein subjected to co-immunoprecipitation and western blot analysis as described in Figure 1 . apoptotic proteins for survival in order to determine the efficacy of venetoclax in treating multiple myeloma. Previous research has shown venetoclax to be highly effective in the treatment of myeloma cell lines and patient samples that harbor t (11;14) . 15 In order to broaden the pool of patients who may benefit from this drug, we chose non-t (11;14) cell lines for our study. We tested the responses of five commonly used myeloma cell lines to treatment with venetoclax and found none to be sensitive. Interestingly, we have previously shown three of these cell lines to be sensitive to ABT-737, suggesting a co-dependence on Mcl-1 and Bcl-x L over Mcl-1 and Bcl-2. Upon further investigation, we found that treatment with venetoclax resulted in loss of Bim binding to Bcl-2, as is expected, but also a gain in Bim on Mcl-1. This suggests that at least some of the Mcl-1 in these cells is unoccupied by BH3-only proteins and acts a sink for the Bim released from Bcl-2 by venetoclax, thereby preventing apoptosis. This appears to be the case in four of the five cell lines. Eight thousand two hundred and twenty six cells express high levels of Noxa, which, along with Bim can bind Mcl-1, leaving no unoccupied anti-apoptotic protein to neutralize the Bim that is released from Bcl-2 after treatment. These results suggest venetoclax may not be effective as a single agent, but could be useful combined with agents that induce Noxa or Bim, or alterations in Bim binding. Indeed, when we combined venetoclax with MeL, carfilzomib or Dex, we saw at least additive responses with all cell lines. Importantly, in cell lines where combinations produced greater than additive responses, sub-lethal doses were sufficient to induced apoptosis.
As mentioned above, carfilzomib treatment results in increased Noxa expression and we believed it should be highly active in combination with venetoclax. However, we only saw a greater than additive response in one cell line, KMS18. In the cells treated with low-dose carfilzomib, Bim released from Mcl-1 and Bcl-x L is rebound by Bcl-2, leaving only a small amount available to activate Bax and Bak, and suggesting saturation of Bcl-2 with Bim. When combined, venetoclax prevents the Bim released from Mcl-1 and Bcl-x L from binding Bcl-2 and also results in the loss of Bim from Bcl-2, thereby leading to a greater than additive response. In addition, the greater amount of Bim bound to Bcl-2 under control conditions in KMS18 cells significantly contributes to this response. 16 Dex has been shown to induce Bim expression in pediatric acute lymphoblastic leukemia primary patient samples, 23 and produced the most striking response when combined with venetoclax in our myeloma cell lines.
Evaluation of changes in expression of Bcl-2 family genes in response to Dex and venetoclax alone or in combination revealed that most of the changes occur in response to Dex alone, with minimal changes in response to venetoclax alone. However, when we examined changes in the expression pattern of Bcl-2 family members in response to the combination of Dex and venetoclax, we see alterations with as low as 0.1 μM venetoclax, again suggesting that very little venetoclax is required to produce significant responses when it is combined with the proper therapeutic.
Multiple myeloma requires Mcl-1 for survival and therefore is more likely to be Mcl-1 primed, meaning Mcl-1 is bound by pro-death activator proteins, such as Bim. In Mcl-1 dependent cells there is much less Bim bound to Bcl-2, and when it gets released either it is not enough to activate Bax/Bak and induce mitochondrial outer membrane permeabilization, such as with MM.1s, or there is enough unoccupied Mcl-1 and Bcl-x L that the activators released from Bcl-2 can be rebound by the other anti-apoptotic proteins, as with KMS18. 4, 16 Under these conditions, a second agent is usually required to push the cell over the apoptotic threshold and induce cell death. The subset of multiple myeloma that is sensitive to venetoclax as a single agent harbors the CCND1 translocation t (11;14) , which correlates with increased Bcl-2 priming. 15, 24 Our Co-IP studies revealed that treatment with Dex results in increased Bim expression as well as shifting Bim-binding patterns, such that MM.1s and KMS18 become Bcl-2 dependent ( Figure 6 ). This dependence closely resembles the Bcl-2 priming seen with the CCND1 translocation, thereby rendering cells once resistant to venetoclax exquisitely sensitive. These data provide a striking example of how therapeutic agents can influence mitochondrial priming as was recently demonstrated with dynamic BH3 profiling. 25 Although those studies revealed how overall change in profiling could predict cellular responses, we have shown how specific changes in priming by a therapeutic agent (carfilzomib or Dex) result in potent combination therapies.
When considering treatment combinations it is important to determine the lowest dose of each drug required to obtain a significant response, as the ultimate goal for testing combinations in the lab is to translate them to a clinical setting. We tested the sensitivity of plasma cells from nine patients with either myeloma or plasma cell leukemia for sensitivity to venetoclax alone and in combination with low-dose Dex. The addition of Dex drastically reduced the concentration of venetoclax required to achieve the IC50 in all samples tested. This trend was not dependent on disease subtype as there appears to be no cytogenetic or fluorescence in situ hybridization diagnosis common to all of the patients whose samples we tested. Furthermore, the correlation between our cell line data and patient samples suggests a combination regimen of venetoclax and Dex may translate successfully to the clinic. Interestingly, MM61 was obtained at diagnosis and even though the plasma cell leukemia was shown to be positive for t (11;14) the cells were resistant to venetoclax, suggesting that patients with this subtype may not universally respond to this drug. However, the addition of low-dose Dex significantly sensitized these cells to venetoclax. This should allow for an expansion of the use of venetoclax beyond patients with t(11;14) myeloma. Thus far; only patients with this subset have responded to venetoclax as a single agent and even within these patients, responses have not been uniform. 26 A trial combining venetoclax with bortezomib and Dex in relapsed/refractory myeloma is currently underway (ClinicalTrials.gov Identifier NCT01794507).
